|
1
|
Deng FM and Melamed J: Histologic variants
of renal cell carcinoma: does tumor type influence outcome? Urol
Clin North Am. 39:119–132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Athar U and Gentile TC: Treatment options
for metastatic renal cell carcinoma: a review. Can J Urol.
15:3954–3966. 2008.PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
|
|
4
|
Yu DS, Chang SY and Ma CP: The expression
of MDR-1-related gp-170 and its correlation with anthracycline
resistance in renal cell carcinoma cell lines and
multidrug-resistant sublines. Br J Urol. 82:544–547. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hartmann JT and Bokemeyer C: Chemotherapy
for renal cell carcinoma. Anticancer Res. 19:1541–1543.
1999.PubMed/NCBI
|
|
6
|
Coppin C: Immunotherapy for renal cell
cancer in the era of targeted therapy. Expert Rev Anticancer Ther.
8:907–919. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dalle S, Thieblemont C, Thomas L and
Dumontet C: Monoclonal antibodies in clinical oncology. Anticancer
Agents Med Chem. 8:523–532. 2008. View Article : Google Scholar
|
|
8
|
Sciarra A, Gentile V, Salciccia S,
Alfarone A and Di Silverio F: New anti-angiogenic targeted therapy
in advanced renal cell carcinoma (RCC): current status and future
prospects. Rev Recent Clin Trials. 3:97–103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Simpson D and Curran MP: Temsirolimus: in
advanced renal cell carcinoma. Drugs. 68:631–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lam JS, Pantuck AJ, Belldegrun AS and
Figlin RA: Protein expression profiles in renal cell carcinoma:
staging, prognosis, and patient selection for clinical trials. Clin
Cancer Res. 13:703s–708s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Netto GJ and Cheng L: Emerging critical
role of molecular testing in diagnostic genitourinary pathology.
Arch Pathol Lab Med. 136:372–390. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lingwood D and Simons K: Lipid rafts as a
membrane-organizing principle. Science. 327:46–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jacobson K, Mouritsen OG and Anderson RG:
Lipid rafts: at a crossroad between cell biology and physics. Nat
Cell Biol. 9:7–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Simons K and Toomre D: Lipid rafts and
signal transduction. Nat Rev Mol Cell Biol. 1:31–39. 2000.
View Article : Google Scholar
|
|
15
|
Patra SK: Dissecting lipid raft
facilitated cell signaling pathways in cancer. Biochim Biophys
Acta. 1785:182–206. 2008.PubMed/NCBI
|
|
16
|
Patra SK and Bettuzzi S: Epigenetic
DNA-methylation regulation of genes coding for lipid
raft-associated components: a role for raft proteins in cell
transformation and cancer progression (review). Oncol Rep.
17:1279–1290. 2007.PubMed/NCBI
|
|
17
|
Mollinedo F, de la Iglesia-Vicente J,
Gajate C, et al: Lipid raft-targeted therapy in multiple myeloma.
Oncogene. 29:3748–3757. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hitosugi T, Sato M, Sasaki K and Umezawa
Y: Lipid raft specific knockdown of SRC family kinase activity
inhibits cell adhesion and cell cycle progression of breast cancer
cells. Cancer Res. 67:8139–8148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lang DM, Lommel S, Jung M, et al:
Identification of reggie-1 and reggie-2 as
plasmamembrane-associated proteins which cocluster with activated
GPI-anchored cell adhesion molecules in non-caveolar micropatches
in neurons. J Neurobiol. 37:502–523. 1998. View Article : Google Scholar
|
|
20
|
Stuermer CA, Lang DM, Kirsch F, et al:
Glycosylphosphatidyl inositol-anchored proteins and fyn kinase
assemble in noncaveolar plasma membrane microdomains defined by
reggie-1 and -2. Mol Biol Cell. 12:3031–3045. 2001. View Article : Google Scholar
|
|
21
|
Schulte T, Paschke KA, Laessing U,
Lottspeich F and Stuermer CA: Reggie-1 and reggie-2, two cell
surface proteins expressed by retinal ganglion cells during axon
regeneration. Development. 124:577–587. 1997.PubMed/NCBI
|
|
22
|
Banning A, Tomasovic A and Tikkanen R:
Functional aspects of membrane association of reggie/flotillin
proteins. Curr Protein Pept Sci. 12:725–735. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baumann CA, Ribon V, Kanzaki M, et al: CAP
defines a second signaling pathway required for insulin-stimulated
glucose transport. Nature. 407:202–207. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Riento K, Frick M, Schafer I and Nichols
BJ: Endocytosis of flotillin-1 and flotillin-2 is regulated by Fyn
kinase. J Cell Sci. 122:912–918. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song L, Gong H, Lin C, et al: Flotillin-1
promotes tumor necrosis factor-alpha receptor signaling and
activation of NF-kappaB in esophageal squamous cell carcinoma
cells. Gastroenterology. 143:995–1005. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hazarika P, McCarty MF, Prieto VG, et al:
Up-regulation of Flotillin-2 is associated with melanoma
progression and modulates expression of the thrombin receptor
protease activated receptor 1. Cancer Res. 64:7361–7369. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Santamaría A, Castellanos E, Gómez V, et
al: PTOV1 enables the nuclear translocation and mitogenic activity
of flotillin-1, a major protein of lipid rafts. Mol Cell Biol.
25:1900–1911. 2005.PubMed/NCBI
|
|
28
|
Thorn CC, Freeman TC, Scott N, Guillou PJ
and Jayne DG: Laser microdissection expression profiling of
marginal edges of colorectal tumours reveals evidence of increased
lactate metabolism in the aggressive phenotype. Gut. 58:404–412.
2009. View Article : Google Scholar
|
|
29
|
Lin C, Wu Z, Lin X, et al: Knockdown of
FLOT1 impairs cell proliferation and tumorigenicity in breast
cancer through upregulation of FOXO3a. Clin Cancer Res.
17:3089–3099. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gómez V, Sesé M, Santamaría A, et al:
Regulation of aurora B kinase by the lipid raft protein
flotillin-1. J Biol Chem. 285:20683–20690. 2010.PubMed/NCBI
|
|
31
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Delahunt B, Sika-Paotonu D, Bethwaite PB,
William Jordan T, Magi-Galluzzi C, Zhou M, Samaratunga H and
Srigley JR: Grading of clear cell renal cell carcinoma should be
based on nucleolar prominence. Am J Surg Pathol. 35:1134–1139.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang SH, Wang CJ, Shi L, et al: High
expression of FLOT1 is associated with progression and poor
prognosis in hepatocellular carcinoma. PLoS ONE. 8:e647092013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pust S, Klokk TI, Musa N, et al:
Flotillins as regulators of ErbB2 levels in breast cancer.
Oncogene. 32:3443–3451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lin C, Wu Z, Lin X, et al: Knockdown of
FLOT1 impairs cell proliferation and tumorigenicity in breast
cancer through upregulation of FOXO3a. Clin Cancer Res.
17:3089–3099. 2011. View Article : Google Scholar : PubMed/NCBI
|
